KIDS Quote, Financials, Valuation and Earnings

Innovative Eyewear has a net margin of -14.51% compared to OrthoPediatrics's net margin of -678.5%. OrthoPediatrics's return on equity of -7.63% beat Innovative Eyewear's return on equity of -113.55%.

OrthoPediatrics has a consensus price target of $40.17, signalling upside risk potential of 75.48%. On the other hand Innovative Eyewear has an analysts' consensus of -- which suggests that it could grow by 178.89%. Given that Innovative Eyewear has higher upside potential than OrthoPediatrics, analysts believe Innovative Eyewear is more attractive than OrthoPediatrics.

OrthoPediatrics has a beta of 1.143, which suggesting that the stock is 14.295% more volatile than S&P 500. In comparison Innovative Eyewear has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OrthoPediatrics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrthoPediatrics pays -- of its earnings as a dividend. Innovative Eyewear pays out -- of its earnings as a dividend.

OrthoPediatrics quarterly revenues are $54.6M, which are larger than Innovative Eyewear quarterly revenues of $253.6K. OrthoPediatrics's net income of -$7.9M is lower than Innovative Eyewear's net income of -$1.7M. Notably, OrthoPediatrics's price-to-earnings ratio is -- while Innovative Eyewear's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrthoPediatrics is 2.77x versus 3.27x for Innovative Eyewear. Usually stocks with elevated PS ratios are considered overvalued.

NexGel has a net margin of -14.51% compared to OrthoPediatrics's net margin of -23.57%. OrthoPediatrics's return on equity of -7.63% beat NexGel's return on equity of -67.5%.

OrthoPediatrics has a consensus price target of $40.17, signalling upside risk potential of 75.48%. On the other hand NexGel has an analysts' consensus of -- which suggests that it could grow by 27.66%. Given that OrthoPediatrics has higher upside potential than NexGel, analysts believe OrthoPediatrics is more attractive than NexGel.

OrthoPediatrics has a beta of 1.143, which suggesting that the stock is 14.295% more volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OrthoPediatrics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrthoPediatrics pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.

OrthoPediatrics quarterly revenues are $54.6M, which are larger than NexGel quarterly revenues of $2.9M. OrthoPediatrics's net income of -$7.9M is lower than NexGel's net income of -$693K. Notably, OrthoPediatrics's price-to-earnings ratio is -- while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrthoPediatrics is 2.77x versus 4.28x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies has a net margin of -14.51% compared to OrthoPediatrics's net margin of -1700%. OrthoPediatrics's return on equity of -7.63% beat SINTX Technologies's return on equity of -132.95%.

OrthoPediatrics has a consensus price target of $40.17, signalling upside risk potential of 75.48%. On the other hand SINTX Technologies has an analysts' consensus of -- which suggests that it could grow by 1751.85%. Given that SINTX Technologies has higher upside potential than OrthoPediatrics, analysts believe SINTX Technologies is more attractive than OrthoPediatrics.

OrthoPediatrics has a beta of 1.143, which suggesting that the stock is 14.295% more volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.497, suggesting its more volatile than the S&P 500 by 49.673%.

OrthoPediatrics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrthoPediatrics pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

OrthoPediatrics quarterly revenues are $54.6M, which are larger than SINTX Technologies quarterly revenues of $367K. OrthoPediatrics's net income of -$7.9M is lower than SINTX Technologies's net income of -$6.2M. Notably, OrthoPediatrics's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrthoPediatrics is 2.77x versus 1.04x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Staar Surgical has a net margin of -14.51% compared to OrthoPediatrics's net margin of 11.27%. OrthoPediatrics's return on equity of -7.63% beat Staar Surgical's return on equity of 5.46%.

OrthoPediatrics has a consensus price target of $40.17, signalling upside risk potential of 75.48%. On the other hand Staar Surgical has an analysts' consensus of $41.89 which suggests that it could grow by 73.01%. Given that OrthoPediatrics has higher upside potential than Staar Surgical, analysts believe OrthoPediatrics is more attractive than Staar Surgical.

OrthoPediatrics has a beta of 1.143, which suggesting that the stock is 14.295% more volatile than S&P 500. In comparison Staar Surgical has a beta of 0.587, suggesting its less volatile than the S&P 500 by 41.304%.

OrthoPediatrics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Staar Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrthoPediatrics pays -- of its earnings as a dividend. Staar Surgical pays out -- of its earnings as a dividend.

OrthoPediatrics quarterly revenues are $54.6M, which are smaller than Staar Surgical quarterly revenues of $88.6M. OrthoPediatrics's net income of -$7.9M is lower than Staar Surgical's net income of $10M. Notably, OrthoPediatrics's price-to-earnings ratio is -- while Staar Surgical's PE ratio is 55.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrthoPediatrics is 2.77x versus 3.51x for Staar Surgical. Usually stocks with elevated PS ratios are considered overvalued.